GSK vets the­o­rize that a mi­to­chon­dr­i­al tar­get may un­lock Parkin­son's and ALS treat­ments in new start­up

Can tar­get­ing a mi­to­chon­dr­i­al path­way pre­vi­ous­ly thought to be un­drug­gable crack the code in dev­as­tat­ing neu­rode­gen­er­a­tive dis­eases, such as Parkin­son’s and ALS? For a new British start­up, that’s the £16 mil­lion ques­tion.

NRG Ther­a­peu­tics un­veiled its Se­ries A ear­ly Wednes­day morn­ing on the backs of two GSK vets and their re­search that, they claim, has pin­point­ed a way to pro­tect mi­to­chon­dria from the hall­mark neu­ronal dam­age seen in neu­rode­gen­er­a­tion. If every­thing goes ac­cord­ing to plan, the biotech could de­vel­op “dis­ease-mod­i­fy­ing” small mol­e­cule treat­ments for both Parkin­son’s and ALS, CEO Neil Miller told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER